Filter
947
Text search:
Price,
R.
Featured
93
229
Language
Document type
437
274
125
48
26
15
14
3
3
1
1
Countries
64
28
26
18
16
15
15
14
14
13
12
11
11
11
10
9
9
9
9
9
9
9
8
7
7
7
7
7
6
6
6
6
6
5
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
287
97
65
54
39
17
5
Toolboxes
106
76
75
36
34
34
34
33
31
28
28
22
18
16
16
13
13
13
9
7
6
3
3
2
1
1
1
In 2015, the United Nations set important targets to reduce premature
cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately
bears the brunt of CVD burden and has one of the highest risks of dying
from non-communicable diseases (NCDs) worldwide. There is currently
an epide
...
Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma
...
This document by Medicines for Malaria Venture (MMV) highlights the significant burden of malaria on children worldwide, emphasizing the need for effective prevention, diagnosis, and treatment strategies. It reviews current challenges and progress in combating pediatric malaria, advocating for conti
...
This document introduces four strategic objectives and twelve operational principles for good pharmaceutical procurement. These objectives and principles have been developed and endorsed by the Interagency Pharmaceutical Coordination Group (IPC), involving the pharmaceutical advisers of the United
...
Good Practice Review
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov
...
The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV gen
...
Towards the Peoples Health Assembly Book - 5
Towards the Peoples Health Assembly Book - 1
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Towards the Peoples Health Assembly Book -5
Towards the Peoples Health Assembly Book -1
